- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
CorVista Health Demonstrates High-Sensitivity for Noninvasive CAD Detection
New study shows promise for identifying ischemia without obstructed arteries.
Mar. 30, 2026 at 5:11pm
Got story updates? Submit your updates here. ›
CorVista Health, a medical technology company, has announced the results of a new study demonstrating the high sensitivity of its noninvasive diagnostic platform for detecting coronary artery disease (CAD), including a condition known as ischemia with no obstructed coronary arteries (INOCA).
Why it matters
This breakthrough could lead to earlier and more accurate diagnosis of heart disease, allowing for earlier intervention and potentially better outcomes for patients. INOCA is a challenging condition to diagnose, so a noninvasive test that can reliably identify it is an important advancement.
The details
The study evaluated CorVista's technology, which uses a combination of electrocardiogram (ECG) and other physiological measurements, to assess its ability to detect CAD and INOCA. The results showed the platform had a sensitivity of over 90% for identifying CAD, including a high sensitivity for INOCA, which is often missed by traditional testing methods.
- The study was conducted in March 2026.
The players
CorVista Health
A medical technology company developing noninvasive diagnostic tools for heart disease.
What’s next
CorVista plans to continue clinical trials and work towards regulatory approval for its diagnostic platform, which could provide a new tool for early detection of heart disease.
The takeaway
This research demonstrates the potential for CorVista's technology to revolutionize the diagnosis of coronary artery disease, including hard-to-detect conditions like INOCA. If validated in further studies, this could lead to earlier intervention and better outcomes for patients.
